Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization

BMC Cancer

Chul-Woo Kim²  Yoon-Kyung Jeon²  Jong-Kuen Lee¹  Ji-Young Jang¹ 

[1]Tumor Immunity Medical Research Center, Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul 110-799, Korea

[2]Department of Pathology, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul 110-799, Korea

关键词: Tumor-associated macrophages (TAM);    Tumor microenvironment;    miR-16;    Exosomes;    EGCG;   

Others  :  1079569
DOI  :  10.1186/1471-2407-13-421

 received in 2012-11-08, accepted in 2013-09-09,  发布年份 2013

【 摘 要 】

Background

Tumor-associated macrophages (TAM) play an important role in tumor microenvironment. Particularly, M2 macrophages contribute to tumor progression, depending on the expression of NF-κB. Tumor-derived exosomes can modulate tumor microenvironment by transferring miRNAs to immune cells. Epigallocatechin gallate (EGCG) has well known anti-tumor effects; however, no data are available on the influence of EGCG on communication with cancer cells and TAM.

Methods

Murine breast cancer cell lines, 4T1, was used for in vivo and ex vivo studies. Exosome was extracted from EGCG-treated 4T1 cells, and the change of miRNAs was screened using microarray. Tumor cells or TAM isolated from murine tumor graft were incubated with exosomes derived from EGCG-treated and/or miR-16 inhibitor-transfected 4T1 cells. Chemokines for monocytes (CSF-1 and CCL-2), cytokines both with high (IL-6 and TGF-β) and low (TNF-α) expression in M2 macrophages, and molecules in NF-κB pathway (IKKα and Iκ-B) were evaluated by RT-qPCR or western blot.

Results

EGCG suppressed tumor growth in murine breast cancer model, which was associated with decreased TAM and M2 macrophage infiltration. Expression of chemokine for monocytes (CSF-1 and CCL-2) were low in tumor cells from EGCG-treated mice, and cytokines of TAM was skewed from M2- into M1-like phenotype by EGCG as evidenced by decreased IL-6 and TGF-β and increased TNF-α. Ex vivo incubation of isolated tumor cells with EGCG inhibited the CSF-1 and CCL-2 expression. Ex vivo incubation of TAM with exosomes from EGCG-treated 4T1 cells led to IKKα suppression and concomitant I-κB accumulation; increase of IL-6 and TGF-β; and, decrease of TNF-α. EGCG up-regulated miR-16 in 4T1 cells and in the exosomes. Treatment of tumor cells or TAM with exosomes derived from EGCG-treated and miR-16-knock-downed 4T1 cells restored the above effects on chemokines, cytokines, and NF-κB pathway elicited by EGCG-treated exosomes.

Conclusions

Our data demonstrate that EGCG up-regulates miR-16 in tumor cells, which can be transferred to TAM via exosomes and inhibits TAM infiltration and M2 polarization. We suggest a novel mechanism by which EGCG exerts anti-tumor activity via regulation of TAM in tumor microenvironment.

【 授权许可】

   
2013 Jang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Gezgen G, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K: Metabolic syndrome and breast cancer: an overview. J Buon 2012, 17:223-229.
• [2]Kelsey JL, Gammon MD: The epidemiology of breast cancer. CA Cancer J Clin 1991, 41:146-165.
• [3]Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC: Diet, nutrition and the prevention of cancer. Public Health Nutr 2004, 7:187-200.
• [4]Yang CS, Sang S, Lambert JD, Hou Z, Ju J, Lu G: Possible mechanisms of the cancer-preventive activities of green tea. Mol Nutr Food Res 2006, 50:170-175.
• [5]Mukhtar H, Ahmad N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 2000, 71:1698S-1702S.
• [6]Lambert JD, Hong J, Yang GY, Liao J, Yang CS: Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr 2005, 81:284S-291S.
• [7]Stuart EC, Scandlyn MJ, Rosengren RJ: Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci 2006, 2006(79):2329-2336.
• [8]Zhang G, Miura Y, Yagasaki K: Effects of green, oolong and black teas and related components on the proliferation and invasion of hepatoma cells in culture. Cytotechnology 1999, 31:37-44.
• [9]Lu G, Liao J, Yang G, Reuhl KR, Hao X, Yang CS: Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Res 2006, 66:11494-11501.
• [10]Lu YP, Lou YR, Xie JG, et al.: Topical applications of caffeine or (−)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci U S A 2002, 99:12455-12460.
• [11]Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK: Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett 2007, 245:232-241.
• [12]Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H: Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004, 64:8715-8722.
• [13]Wang ZY, Huang MT, Ho CT, et al.: Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res 1999, 52:6657-6665.
• [14]Heijnen HF, Schiel AE, Fijnheer R, et al.: Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alphagranules. Blood 1999, 94:3791-3799.
• [15]Rozmyslowicz T, Majka M, Kijowski J, et al.: Platelet- and megakaryocytederived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS 2003, 17:33-42.
• [16]Majka M, Janowska-Wieczorek A, Ratajczak J, et al.: Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 2001, 97:3075-3085.
• [17]Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, Kim S: Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003, 39:184-191.
• [18]Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L: Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008, 15:80-88.
• [19]Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, Howell SB: Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005, 4:1595-1604.
• [20]Millimaggi D, Mari M, D'Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, Pavan A, Dolo V: Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 2007, 9:349-357.
• [21]Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C: Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res 2011, 1:98-110.
• [22]Pollard JW: Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008, 84:623-630.
• [23]Bingle L, Brown NJ, Lewis CE: The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol 2002, 196:254-265.
• [24]Leek RD, Harris AL: Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002, 7:177-189.
• [25]Antonio S, Tiziana S, Alberto M, Paola A: Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 2006, 42:717-727.
• [26]Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A: p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006, 66:11432-11440.
• [27]Mantovani A, Marchesi F, Porta C, Sica A, Allavena P: Inflammation and cancer: breast cancer as a prototype. Breast 2007, 16:S27-S33.
• [28]Paik S, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
• [29]Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG: MicroRNAs modulate the noncanonical NF-κB pathway by regulating IKKα expression during macrophage differentiation. Nat Immunol 2010, 11:799-805.
• [30]Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR: Re-educating tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008, 205:1261-1268.
• [31]Shih JY, Jeremy AY, Chen JW, Yang PC: Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol 2006, 2:101-106.
• [32]Bobrie A, Colombo M, Krumeich S, Raposo G, Théry C: Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. J Extracellular Vesicles 2012, 1:18397.
• [33]Chew V, Toh HC, Abastado JP: Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol 2012, 2012:1-10.
• [34]Théry C: Exosomes: secreted vesicles and intercellular communications. F1000 Biology Reports 2011, 3:15.
• [35]Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L: Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2010, 78:838-848.
• [36]Rustom A, Saffrich R, Markovic I, et al.: Nanotubular highways for intercellular organelle transport. Science 2004, 303:1007-1010.
• [37]Sherer NM, Mothes W: Cytonemes and tunnelling nanotubules in cell-cell communication and viral pathogenesis. Trends Cell Biol 2008, 18:414-420.
• [38]Ratajczak J, Wysoczynski M, Hayek F, et al.: Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006, 20:1487-1495.
• [39]Hutagalung AH, Novick PJ: Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev 2011, 91:119-149.
• [40]Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al.: Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10:1470-1476.
• [41]Pillai RS: MicroRNA function: multiple mechanisms for a tiny RNA? RNA 2005, 11:1753-1761.
• [42]Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM: Selective release of MicroRNA species from normal and malignant mammary epithelial cells. PLoS One 2010, 5:e13515.
• [43]Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X: miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 2008, 36:5391-5404.
• [44]Ofir M, Hacohen D, Ginsberg D: miR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res 2011, 9:440-447.
• [45]Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D’Urso L, Pagliuca A, Biffoni M, Labbaye C, Bartucci M, Muto G, Peschle C, De Maria R: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008, 14:1271-1277.
• [46]Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D, Ochiya T: Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010, 18:181-187.
• [47]Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H, Lu X: Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res 2010, 70:7176-7186.
• [48]Thorsten H, Subhra KB, Toby L, Antonio S, Claire EL: Regulation of macrophage function in tumors: the multifaceted role of NF-κB. Blood 2009, 113:3139-3146.